STI-6643 / Sorrento - LARVOL DELTA

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Sorrento Therapeutics, Inc. | Trial completion date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Sep 2024 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Sorrento Therapeutics, Inc. | N=24 ➔ 100 | Trial primary completion date: Mar 2024 ➔ Sep 2024

Enrollment change • Trial primary completion date • Oncology • Solid Tumor

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Sorrento Therapeutics, Inc. | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Mar 2022 ➔ Mar 2024

Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells. (PubMed, Front Oncol) - "Of particular interest, STI-6643 preserved T cell functionality in vitro and showed significantly lower immune cell depletion in vivo in contrast to three previously published competitor reference anti-CD47 clones Hu5F9, AO-176 and 13H3. Finally, STI-6643 displayed comparable anti-tumor activity to the high-affinity reference clone Hu5F9 in a RAJI-Fluc xenograft tumor model as monotherapy or in combination with anti-CD20 (rituximab) or anti-CD38 (daratumumab) mAbs. These data suggest that STI-6643 possesses the characteristics of an effective therapeutic candidate given its potent anti-tumor activity and low toxicity profile."

IO biomarker • Journal • Oncology • CD47 • SIRPA

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Sorrento Therapeutics, Inc.; Not yet recruiting ➔ Recruiting; Initiation date: Aug 2021 ➔ Nov 2021

Clinical • Enrollment open • Trial initiation date • Oncology • Solid Tumor

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (GlobeNewswire) - “Sorrento Therapeutics...announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference...The conference is being held virtually on September 13-15, 2021…Abivertinib: Phase 3 topline data in NSCLC available Q4 2021…IND for Phase 2 in Prostate Cancer to be filed Q4 2021. PD-L1 antibody: In Phase 3 for SCLC and NDA submission in China for recurrent or metastatic cervical cancer. CD38 ADC: In Phase 1 for Amyloidosis and Multiple Myeloma. CD38 DAR-T: In Phase 1 for Relapsed and Refractory Multiple Myeloma. CD47 antibody: In Phase 1 in solid tumors. SOFUSA: Lymphatic delivery of Enbrel in Phase 1b in refractory rheumatoid arthritis patients.”

Clinical data • IND • P3 data: top line • Cervical Cancer • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor

Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: Sorrento Therapeutics, Inc.

Clinical • New P1 trial • Oncology • Solid Tumor

Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies (GlobeNewswire) - "Sorrento Therapeutics, Inc...announced that the FDA has cleared Sorrento’s internally developed anti-CD47 monoclonal antibody, STI-6643, which was discovered from Sorrento's G-MAB™ library, for an initial clinical trial. The initial clinical trial will be a basket trial entitled 'A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of STI-6643, an Anti-CD47 Human Monoclonal Antibody, in Patients with Selected Relapsed or Refractory Malignancies.'"

IND • Hematological Malignancies • Oncology